Results 11 to 20 of about 197,589 (314)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. [PDF]

, 2012
INTRODUCTION: Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivity are inversely correlated by standard criteria. However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein
Yarnold, J, Drury, Suzanne, Barrett-Lee, P, Hills, Margaret, Salter, J, Lawrence, D, Harnett, AM, Cuzick, J, Earl, H, Sestak, I, Ma, NCRIABCT, Georges Sumo, A'Hern, R, Sestak, Ivana, Barrett-Lee, Peter Jeffrey, Dowsett, M, A'Hern, Roger, Robinson, A, Perren, T, Johnson, L, Harris, Adrian, George, WD, Bliss, JM, Dodwell, D, null null, Peter Barrett-Lee, Price, D, Foster, L, Poole, C, Isabel Pinhel, Suzanne Drury, Fernando, I, Dowsett, Mitch, Cuzick, Jack, Judith M Bliss, Barrett-Lee, Peter, Sumo, G, Raina, V, Hills, M, Roger A'Hern, Ivana Sestak, Adrian Harris, Janine Salter, Jack Cuzick, Bliss, Judith M., Brunt, AM, Peto, J, Drury, S, Bliss, Judith M, Sumo, Georges, Margaret Hills, Mitch Dowsett, Pinhel, Isabel, Harris, A, NCRI Adjuvant Breast Cancer Trial Management Group, Bliss, M, Pinhel, I, Salter, Janine   +57 more
core   +1 more source

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Lebeau, Annette, Annette Lebeau
core   +1 more source

Updated recommendations for HER2 testing in the UK [PDF]

, 2004
This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK.
Pinder, S.E., Bartlett, J, Humphreys, S., Dowsett, M, Ellis, I O, Jasani, B, Ellis, I.O., Walker, R, Bartlett, J.M.S., Miller, K, Humphreys, S, Pinder, S E; id_orcid, Rhodes, A, Walker, R., Miller, K., Jasani, B., Rhodes, A., Dowsett, M.   +17 more
core   +1 more source

MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway

Cancer Biology & Therapy, 2023
Objective: Human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) is associated with poor prognosis. This study aimed to elucidate the role of miR−18a−5p in regulation of HER2+-BC progression along with its mechanism of action ...
Yongjun Liu, Hua Yang
doaj   +1 more source

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) [PDF]

, 2005
Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC).
Heinrich, B., Stemmler, H. J., Kahlert, S., Heinemann, Volker, Siekiera, W., Untch, M.   +5 more
core   +1 more source

Pattern of HER2 Overexpression in Urinary Bladder Carcinomas in Kano, Nigeria

The Annals of African Surgery, 2023
Background: The worldwide distribution of bladder cancer varies, conforming to differences in environmental and genetic risk factors. HER2 neu is overexpressed in many human cancers, including urinary bladder carcinomas.
Muhammad Sanusi Haruna, Akinfenwa Taoheed Atanda, Yawale Iliyasu   +2 more
doaj   +1 more source

Calmodulin binds HER2 and modulates HER2 signaling

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
Human epidermal growth factor receptor 2 (HER2), a member of the ErbB family of receptor tyrosine kinases, has defined roles in neoplastic transformation and tumor progression. Overexpression of HER2 is an adverse prognostic factor in several human neoplasms and, particularly in breast cancer, correlates strongly with a decrease in overall patient ...
White, Colin D., Li, Zhigang, Sacks, David B.   +2 more
openaire   +2 more sources

Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab [PDF]

, 2005
Background: HER2 is overexpressed in 20 - 30% of breast cancers. Compared to chemotherapy alone, chemotherapy with trastuzumab improves clinical outcome in patients with HER2- positive metastatic breast cancer ( MBC). In general, HER2 status in a primary
Lässig, D., Stemmler, H. J., Stieber, P., Heinemann, Volker   +3 more
core   +1 more source

Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers

European Journal of Breast Health, 2019
Objective:Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumor suppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss
Melek Ünçel, Gülden Diniz, Gamze Aköz, Zübeyde Yıldırım Ekin, Sevil Sayhan, Serdar Yardım, Semra Salimoğlu   +6 more
doaj   +1 more source

Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines

South Asian Journal of Cancer, 2022
Biren Parikh Introduction Hormonal status and HER2 expression are valuable biomarkers and dictate the management of the patients diagnosed with invasive breast cancer (IBC).
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel   +4 more
doaj   +1 more source